Literature DB >> 19117598

Intraoperative gross assessment of myometrial invasion and cervical involvement in endometrial cancer: Role of tumor grade and size.

Stelios Fotiou1, Nikos Vlahos, Agatha Kondi-Pafiti, Petros Zarganis, Katerina Papakonstantinou, George Creatsas.   

Abstract

OBJECTIVES: To evaluate the accuracy of visual examination of myometrial invasion and the involvement of the cervix in the hysterectomy specimen and to explore the role of tumor grade and size in the accuracy of gross estimation of myometrial invasion.
METHODS: In 142 patients with apparent early endometrial cancer the uterus was opened after its removal and inspected. The size of the tumor (<or= or >2 cm), the depth of myometrial invasion (less or greater than 50%) and the involvement of the cervix (as positive or negative) were visually estimated and recorded. All patients underwent surgical staging. The gross findings were compared with the final histological results. Estimations of myometrial invasiveness were analyzed according to the tumor grade and size. Accuracy, specificity, sensitivity, positive and negative predictive values were calculated.
RESULTS: The overall accuracy rate for myometrial invasion was 81.7% (116/142). False positive and false negative results noted in 17/101 (17%) and 9/41 (21.9%) of patients. Sensitivity, specificity, positive and negative predictive values were 78%, 83.2%, 65.3% and 90.3% respectively. Gross estimation of invasion was more often successful in patients with smaller (<or=2 cm) than in those with grater tumors (accuracy 88.9% vs. 79.2%). Increasing tumor grade found to diminish the rate of correct prediction. The accuracy for grade I tumors was 93.5%, for grade II 80.4% and only 58.6% for grade III lesions. Cervical involvement was correctly evaluated in 138/142 patients with one false positive and 3 false negative results.
CONCLUSION: These data show that gross estimation of myometrial invasion is highly accurate in small (<or=2 cm) and grade I tumors. Visual evaluation of cervical involvement is also reliable. However, prediction of myometrial invasion is lower in tumors with higher grade, being poor in grade III lesions. Inaccuracies of preoperative histology may decrease the sensitivity of intraoperative assessment based on final grade.

Entities:  

Mesh:

Year:  2008        PMID: 19117598     DOI: 10.1016/j.ygyno.2008.11.009

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a review of 67 patients.

Authors:  Salih Taşkın; Fırat Ortaç; Korhan Kahraman; Göksu Göç; Derya Oztuna; Mete Güngör
Journal:  Int J Clin Oncol       Date:  2011-11-18       Impact factor: 3.402

2.  Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer.

Authors:  Jianpei Li; Jianhua Lin; Yaoling Luo; Miaohuan Kuang; Yijun Liu
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

3.  Preoperative tumor size is associated with deep myometrial invasion and lymph node metastases and is a negative prognostic indicator for patients with endometrial carcinoma.

Authors:  Kohei Nakamura; Kentaro Nakayama; Noriyoshi Ishikawa; Toshiko Minamoto; Tomoka Ishibashi; Kaori Ohnishi; Hitomi Yamashita; Ruriko Ono; Hiroki Sasamori; Sultana Razia; Mohammad Mahmud Hossain; Shanta Kamrunnahar; Masako Ishikawa; Satoru Kyo
Journal:  Oncotarget       Date:  2018-05-01

4.  Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma.

Authors:  Dan Wang; Jia-Xin Yang; Dong-Yan Cao; Xi-Run Wan; Feng-Zhi Feng; Hui-Fang Huang; Keng Shen; Yang Xiang
Journal:  Onco Targets Ther       Date:  2013-03-16       Impact factor: 4.147

5.  High preoperative Glasgow prognostic score is a negative prognostic factor for patients with endometrial carcinoma.

Authors:  Kohei Nakamura; Kentaro Nakayama; Toshiko Minamoto; Tomoka Ishibashi; Kaori Sanuki; Hitomi Yamashita; Ruriko Ono; Hiroki Sasamori; Takayoshi Komatsu-Fujii; Masako Ishikawa; Satoru Kyo
Journal:  Mol Clin Oncol       Date:  2018-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.